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ISG15 is an interferon-stimulated, ubiquitin-like protein, with anti-viral and anti-bacterial
activity. Here, we map the endogenous in vivo ISGylome in the liver following Listeria mono-
cytogenes infection by combining murine models of reduced or enhanced ISGylation with
quantitative proteomics. Our method identifies 930 ISG15 sites in 434 proteins and also
detects changes in the host ubiquitylome. The ISGylated targets are enriched in proteins
which alter cellular metabolic processes, including upstream modulators of the catabolic and
antibacterial pathway of autophagy. Computational analysis of substrate structures reveals
that a number of ISG15 modifications occur at catalytic sites or dimerization interfaces of
enzymes. Finally, we demonstrate that animals and cells with enhanced ISGylation have
increased basal and infection-induced autophagy through the modification of mTOR, WIPI2,
AMBRA1, and RAB7. Taken together, these findings ascribe a role of ISGylation to temporally
reprogram organismal metabolism following infection through direct modification of a subset
of enzymes in the liver.
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ISG15 is an interferon-induced, ubiquitin-like protein (ubl)with potent antiviral activity1. Similar to ubiquitin, ISG15covalently modifies both cellular and viral substrates following
activation by an E1 enzyme, UBE1L2, conjugation by an E2
enzyme, UBCH83, and ligation by three identified E3 enzymes:
HERC5/6, TRIM25, and HHARI4–7. USP18 is an ISG15-specific
isopeptidase, which deconjugates ISG15 from its substrates8.
However, USP18 is also a major negative regulator of STAT
signaling, independent of its effect on ISGylation9. Canonical
induction of ISG15 occurs following Type I interferon activation
or viral infection; however, ISG15 can also be induced by a variety
of other stimuli, such as retinoic acid, LPS, and genotoxic
stress10–12. In addition, ISG15 can be upregulated in an
interferon-independent manner following infection with bacterial
pathogens, such as Listeria monocytogenes and Mycobacterium
tuberculosis13,14. Murine models of ISG15 deficiency and studies
in human cell lines have demonstrated that ISG15 and ISGylation
broadly target numerous viruses1,15. Isg15-deficient animals
develop normally, but are susceptible to both viral and bacterial
pathogens upon challenge11,13,15–17. Furthermore, many viruses
express ISG15 deconjugases or nonstructural proteins that pre-
vent conjugation, suggesting evolutionary pressure to dismantle
ISGylation for effective viral replication18–20. In this vein, an
isopeptidase dead mutant of USP18C61A/C61A, which leads to
enhanced ISGylation following ISG15 induction, is resistant to
viral infection, while its susceptibility to bacterial infection is
unknown21.
Despite the initial identification of ISG15 as an antiviral
molecule, patients who lack Isg15 do not appear to be overly
sensitive to viral infection, instead they have difficulty clearing
bacterial infections or the BCG vaccine due to reduced interferon
gamma immunity22. Patients who lack ISG15 also develop an
Aicardi-Goutières-like interferonopathy in the brain23. This was
reported to originate from the destabilization of USP18, due to its
role in STAT signaling. In addition, ISG15 functions through
three distinct modes of action, which likely play complementary
roles in various tissues following infection. ISG15 can be secreted
and act as a cytokine24,25, has antiviral effects through non-
covalent interactions26, and ISGylation can also reduce viral
replication and viral load through covalent modification of viral
and/or cellular targets27,28. In contrast to ubiquitin, the
mechanistic consequences of ISGylation are not fully elucidated.
However, several general themes have emerged regarding its
function. ISG15 can modify nascent viral proteins co-transla-
tionally, thereby interfering with virion self-assembly29. ISGyla-
tion of cellular proteins alters trafficking, reducing both viral
budding and exosome secretion, while increasing canonical
cytokine secretion13,30–32. Finally, there are also several instances
of ISGylation competing with ubiquitin to temporarily stabilize
proteins that would otherwise be degraded33.
In order to better understand the consequences of ISG15
modification on protein fate, we systematically identified endo-
genous ISG15 substrates following infection in vivo with the
bacterial pathogen, Listeria monocytogenes. Enrichment of pep-
tide remnants left by posttranslational modifications after trypsin
digestion coupled with identification of the precise site of mod-
ification through mass spectrometry has been extremely fruitful
in unraveling mechanisms of action of other modifications, such
as acetylation34, ubiquitination35–37, and SUMOylation38–40.
While several studies have identified ISGylated targets through
proteomics41–44, these approaches primarily relied either on
ectopic expression of ISG15 in tissue culture cells, which could
lead to overexpression artifacts, or interferon treatment of pri-
mary cells, which could deliver a stronger stimulus than that
which is physiologically induced by a viral or bacterial infection.
It has been challenging to differentiate between ISG15, ubiquitin,
and NEDD8 sites because these UBLs share the same diglycine
adduct following digestion with trypsin. A recent study used a
distinct immuno-enrichment strategy to purify ubiquitin sites
in vitro45. However, thus far no one has been able to specifically
identify ISGylated sites either in vitro or in vivo.
Here, we address this obstacle by defining the quantitative,
proteome-wide ubiquitylome in Isg15-deficient animals prior to
and following infection. We highlight sites that arise during Lis-
teria infection in wild-type animals, as well as in mice with
enhanced ISGylation due to knock in of an inactive ISG15
deconjugase (USP18C61A/C61A). Our strategy reveals 930 endo-
genous sites on 434 ISG15 substrates in the liver in the context of
a clinically relevant infection. Unlike for SUMOylation, there is
neither a discernable consensus motif for modification nor an
enrichment of modification sites in a specific cellular compart-
ment. Interestingly, ISG15 modifies metabolic enzymes on lysines
at dimerization interfaces and catalytic sites in the liver. In par-
ticular, ISGylation targets four key regulators of autophagy and
leads to upregulation of this pathway following infection both
in vivo and in vitro.
Results
Strategy for Identification of bona fide ISG15 sites. In order to
elucidate mechanisms of action of ISG15, we used mass spec-
trometry (MS)-based proteomics to identify ISG15 modification
sites in an unbiased manner. We analyzed liver tissue from mice
infected with Listeria monocytogenes and enriched peptides that
carry a diglycine adduct following digestion with trypsin. To
distinguish bona fide ISGylation sites from ubiquitin sites, which
share a conserved C-terminal LRLRGG motif (Fig. 1a), we
compared wild-type (WT) mice with Isg15-deficient mice (KO).
In addition, we mapped sites in mice bearing a knock-in (KI)
mutation in USP18C61A/C61A, which renders it catalytically
inactive, leading to hyper-ISGylation following infection, a con-
dition which is biologically interesting in addition to being a
positive control for our screen (Fig. 1a). USP18 has two distinct
mechanisms of action: (i) it removes ISG15 from substrates and
(ii) it negatively regulates STAT signaling9. Since USP18 deletion
cannot distinguish between these functions, we first assessed
whether the deconjugase-dead (USP18C61A/C61A) mouse would
be resistant to Listeria infection. USP18C61A/C61A mice exhibit
increased resistance to viral infection, but are otherwise pheno-
typically indistinguishable from wild-type littermates21. However,
surprisingly Listeria infection of USP18C61A/C61A mice leads to a
significant increase in bacterial load in the liver relative to wild-
type controls (Fig. 1b). While there was also a slight but sig-
nificant increase in bacterial burden in the spleen in USP18C61A/
C61A animals, the bacterial counts in the liver indicated an unu-
sual susceptibility in that organ. Histological sections of infected
liver revealed larger more diffuse bacterial foci which penetrated
into neighboring hepatocytes in USP18C61A/C61A animals,
whereas in wild-type animals the bacteria were primarily con-
tained within immune cells (Fig. 1c). In addition, Gram staining
confirmed the presence of many more bacteria per focus in
USP18C61A/C61A, relative to wild-type animals, as the CFUs per
organ indicated (Fig. 1c). Accordingly, the liver tissue from
infected USP18C61A/C61A mice also displayed enhanced ISGyla-
tion compared with the WT (Fig. 1d). Together, these data
indicate a tissue-specific role for ISGylation in the liver upon
Listeria infection, and provided a rationale to map ISG15 sites in
the liver of USP18C61A/C61A animals compared with wild-type
animals.
Consequently, for the proteomics analysis, we infected Isg15−/−,
wild-type, and USP18 C61A/C61A mice via intravenous injection
and harvested liver tissue following 72 h of infection. We also
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included a noninfected cohort. Upon trypsin digestion and
enrichment of diglycine adducts from the liver, diglycine-
modified peptides were identified and quantified. Following
statistical analysis and non-supervised hierarchical clustering,
significantly regulated sites grouped into four major clusters.
Moreover, animals also clustered together by genotype and
condition, indicating the high reproducibility of our approach
(Fig. 2a). Prior to infection, ~1000 ubiquitin sites were identified
across all three conditions (cluster 4). Listeria infection led to a
global downregulation of these ubiquitin sites, as previously
observed for both ubiquitin and SUMO modification in vitro38,46.
We also identified 219 ubiquitin sites that arise following
infection (cluster 3). Most importantly, we were able to identify
614 ISG15 sites on 292 proteins induced by Listeria infection
(cluster 2). The majority of these sites are completely absent in
Isg15−/−-deficient animals as indicated in gray (Fig. 2a, right
panel), and are therefore considered bona fide ISG15 sites. We






















































































Fig. 1 Strategy for Identification of ISG15 sites and the effect of enhanced ISGylation on bacterial infection. a C-terminal amino acid sequence of Ubiquitin,
ISG15, and NEDD8 followed by the experimental design of proteomic identification of ISG15 diglycine sites. Created with Biorender.com. b Colony-forming
units of Listeria monocytogenes per organ following 72 h of infection (5 × 105 colony-forming units injected intravenously into the tail vein); the results
displayed are from three independent experiments, bar indicates mean, wild-type n= 18, USP18C61A/C61A n= 16 (two KI animals died and thus CFUs were
not enumerated) significance for in vivo data determined using Mann–Whitney test. c Representative hemotoxylin and eosin and Gram staining of liver
tissue of animals infected with Listeria monocytogenes for 72 h (wild-type n= 3 and USP18C61A/C61A n= 3). Bacterial foci are indicated by black dotted line.
d SDS-PAGE of liver homogenates from wild-type or USP18C61A/C61A mice following 72 h of infection (representative blot with n= 3 animals per genotype)
with Listeria monocytogenes.
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**** p value < 0.0001
*** p value ≤ 0.0002
* p value ≤ 0.05

















Fig. 2 Identification of in vivo ISGylation sites during Listeria infection. a Heatmap showing significantly regulated GlyGly(K) sites after non-supervised
hierarchical clustering. On the right side, the heatmap is shown with missing values in gray. Four major clusters can be observed corresponding to
ISG15 sites (clusters 1 and 2) and ubiquitin sites (clusters 3 and 4). b Bar chart and Venn diagram showing the number and overlap of ISGylated proteins
identified in this study and previous studies. c Percent of modified proteins from each cluster that are also upregulated following infection according to the
shotgun data from liver tissue prior to diglycine enrichment; Percent of modified sites from each cluster that overlap with published ubiquitin or acetylation
sites. d Sequence logos were drawn based on the sequence alignment of different ISGylation sites and their+ 5 and −5 flanking regions. e GO analysis of
ISGylated proteins (clusters 1 and 2) relative to all proteins identified in this analysis (gray) and all mouse proteins in the Uniprot/Swiss-Prot database
(black). Bars correspond to the percentage of proteins annotated with each GO term. Asterisks indicate significant enrichment relative to the number of
identified proteins (two-sided Fisher's exact test).
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present in USP18C61A/C61A animals (cluster 1). Since USP18 is
concomitantly induced with ISG15 following Listeria infection,
we suspect that certain substrates are deconjugated more rapidly
than others. Future work should address this hypothesis by site
identification during a time course. To avoid mistakenly
identifying ubiquitin or NEDD8 sites as ISG15 sites (due to
possible indirect effects of Isg15 deletion or USP18C61A/C61A
mutation), we assessed whether ubiquitin and NEDD8 levels
appear to vary using SDS-PAGE prior to or following infection
(Supplementary Fig. 1a, b). If anything, ubiquitin and NEDD8-
sites decreased following infection in vivo while ISGylation
increased, as was previously observed for ubiquitin46 and as is a
new observation for NEDD8 (Supplementary Figs. 1b, 2e). In
vitro total ubiquitin did not dramatically change in mouse
embryonic fibroblasts 24 h post infection, whereas NEDD8 was
slightly reduced (Supplementary Fig. 1e). Furthermore, a
comparison of sites identified by quantitative diglycine enrich-
ment between Isg15−/− and wild-type animals prior to infection
shows no significantly regulated sites (Supplementary Fig. 1g).
Taken together, these data suggest that sites identified by our
method are likely bone fide ISG15 sites and by extension not
misidentified ubiquitin or NEDD8 sites. Ultimately, we identified
930 ISG15 sites on 434 proteins (clusters 1 and 2, Supplementary
Data 1), 87 of which had been previously identified (Fig. 2b;
Supplementary Data 2). Taken together, our approach system-
atically identified endogenous ISG15 modification sites in vivo.
ISG15 can modify known ubiquitin and acetylation sites.
Analysis of the primary amino acid sequences of identified
ISG15 sites did not reveal an obvious amino acid consensus sequence
for the modification (Fig. 2d), as is the case for ubiquitin36,47, but
unlike for SUMO40,48. One proposed mode of action of ISG15 is
cotranslational modification of nascent polypeptides following viral
infection as mediated by the IFN-induced E3 HERC529. Since Lis-
teria can provoke ISG15 induction in an interferon-independent
manner, we assessed whether there was a potential bias toward
ISGylation of proteins induced by infection, which could correlate
with cotranslational modification, as determined by quantitative
proteomics of the input (Supplementary Fig. 2a, Supplementary
Data 3). Comparison with ubiquitinated proteins suggested a lower
percentage of modification of infection-induced ISG15 targets than
that of infection-induced ubiquitin targets (Fig. 2c). It will be
worthwhile to mechanistically determine whether Listeria infection
leads to similar or reduced levels of cotranslational modification
relative to viral infection in future studies.
To date, over 100,000 modification sites have been identified
for ubiquitin; however, one important caveat of these diglycine
enrichment-based studies is that they did not exclude ISG15 and
NEDD8 sites. We therefore compared published ubiquitin sites49
with our identified ISG15 sites (Fig. 2c) in order to assess the
overlap of sites, which could arise from competition between
ubiquitin and ISG15 or misidentified ubiquitin sites. First, sites
identified prior to infection in our screen in Isg15−/− animals
(and therefore expected ubiquitin sites) had an 84% overlap with
published ubiquitin sites. Ubiquitin sites induced by infection
(present in Isg15-deficient animals) had a 75% overlap with
published ubiquitin sites. Notably, sites identified in the condition
of deregulated ISGylation had only a 57% overlap with ubiquitin
sites, whereas those sites which arose in wild-type animals
following Listeria infection had a 71% overlap. Future biochem-
ical analysis of site competition between distinct posttranslational
modifications on specific substrates will be critical to tease apart
distinct functions of ubiquitin and ISG15 under these conditions.
We also compared ISG15 sites with identified acetylation sites.
The percentage of common sites between ISG15 and acetylation
in clusters 1, 3, and 4 was similar (21%, 19%, and 21% of sites,
respectively). Whereas ISG15 sites induced following infection
with Listeria in wild-type mice (cluster 2) have a 31% overlap
with acetylation. Previous work has indicated that acetylation
preferentially targets the metabolic activity of enzymes in the
liver50. While acetylation of specific enzymes can have distinct
effects depending on the enzyme, it is tempting to speculate that
ISGylation could compete for lysines on enzymes that would
otherwise be activated by acetylation during infection to thwart
bacterial acquisition of host nutrients. Taken together, ISGylation
following Listeria infection shows significant overlap with both
ubiquitination and acetylation, suggesting competition for specific
lysines.
ISG15 modifies extracellular and mitochondrial proteins. Gene
ontology analysis of ISGylated proteins for cellular compartments
highlighted a significant enrichment in extracellular proteins in
all infection conditions (Fig. 2e). These results support the pub-
lished role for ISGylation in exosome secretion, as well as the
finding that ISGylation modulates cytokine secretion, and high-
light other potential substrates in addition to TSG101 that could
potentially affect this phenotype13,32,51. The identified ISGylome
following Listeria infection in wild-type animals was significantly
enriched in mitochondrial proteins in liver tissue (Fig. 2c). Recent
work has indicated that ISG15 can affect mitochondrial mor-
phology and function following Vaccinia virus infection; our
identification of an enrichment of mitochondrial proteins that are
ISGylated following Listeria infection is in concordance with
these findings52. Gene ontology analysis of ISGylated proteins for
molecular function revealed an enrichment of proteins that bind
to nucleotides and ATP in both USP18C61A/C61A and wild-type
conditions (Fig. 2e). Following infection of wild-type animals,
there is an enrichment of ISGylation of cofactor and coenzyme-
binding proteins as well as lyase activity, which is absent in
animals with enhanced ISGylation. In addition, gene ontology
analysis of ISGylated proteins for biological processes revealed a
striking enrichment in a number of different metabolic pathways,
including ADP, glutathione, and glucose metabolism as well as
lipid oxidation (Fig. 2e). Taken together, ISG15 modifies a
number of proteins in the liver, which are relevant for the control
of metabolism.
Evidence for ISG15 chains or ISG15/ubiquitin chains. While
our primary goal was to identify ISG15 sites, determining the
strict ubiquitylome in Isg15−/−animals allowed us to gain insight
into how ISG15 and ubiquitin modifications cooperate during an
infection. Indeed, it was immediately apparent that a large
number of ubiquitin sites (cluster 4) disappeared following
infection and that others emerged, likely following transcriptional
upregulation of the ubiquitinated substrate (Fig. 3a, b; Supple-
mentary Fig. 1a, Supplementary Data 4). Interestingly, we also
found evidence for modification of Ubiquitin on K6 and K29 and
modification of ISG15 on K35 in wild-type infection conditions
and on K8 in USP18C61A/C61A KI mice (Fig. 3c). Our analysis
cannot formally differentiate between modification by ubiquitin
and ISG15, since ISG15 is absent in the strict ubiquitylome by
design, however, these data do confirm that K29 of ubiquitin is
modified. Mixed chains between ubiquitin and ISG15 have pre-
viously been identified on this lysine53. Modification of ISG15 on
K8 or K35 (Fig. 3c) has not yet been described so whether this
represents mixed chains of ubiquitin and ISG15 or ISG15-ISG15
chains remains to be determined. Future biochemical studies of
the consequences and nature of these chains following infection
will likely be worthwhile.
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Gene ontology analysis of ubiquitin sites gained and lost
following infection (clusters 3 and 4, respectively) revealed that
certain substrates are similarly enriched among ubiquitin targets
and ISG15 sites (nucleotide binding and cellular metabolic
processes), however, others inversely correlated with ISG15 sites
(cofactor binding, coenzyme binding, lyase and ligase activity,
Fig. 3d). These patterns of enrichment suggest that certain
ubiquitin modifications are replaced with ISG15 modifications
following infection. Interestingly, ISG15 sites on proteins related
to metabolic processes are not significantly enriched among
ubiquitin sites, suggesting that ISGylation specifically targets
proteins that affect metabolism. Whereas, for ubiquitin, there are
several groups of substrates associated with the response to
pathogens, cell death and translation, all of which further
differentiate ubiquitin sites from ISG15 sites.
Structural analysis of ISG15 sites. While there was no discern-
able primary amino acid sequence motif for ISG15 sites, we
hypothesized that there might be specific domains or structural
features targeted by the UBL. We therefore focused on ISG15 sites
in proteins with known crystal structures to search for common
features surrounding the identified target lysines. In several cases,
ISG15 modification occurs on sites of protein/protein interactions,
which can be between several proteins in a complex (Fig. 4a) or at
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Fig. 3 Loss of ubiquitin sites following infection and evidence for mixed ISG15/Ubiquitin chains. a Volcano plot showing significantly regulated ubiquitin
sites upon Listeria infection of Isg15−/− animals. The fold change (in log2) of each GlyGly(K) site is shown on the x-axis, while the statistical significance
(−log P-value) is shown on the y-axis. In total, 168 GlyGly(K) sites were significantly upregulated during infection, while 1138 sites were downregulated
(Supplementary Data 3). b Heatmap representation of significantly up- and downregulated ubiquitin sites after non-supervised hierarchical clustering. On
the right side, the heatmap is shown with missing values in gray (Supplementary Data 4). c Crystal structures of ubiquitin and ISG15 with modified lysines
highlighted. K6 and K29 of ubiquitin are modified following bacterial infection in wild-type animals. K35 of ISG15 is modified following bacterial infection in
wild-type animals, and K8 is modified following infection in USP18C61A/C61A animals. d GO cellular compartment analysis of ubiquitylated proteins (clusters
3 and 4) relative to all proteins identified in the analysis (light gray) and all mouse proteins in the Uniprot/Swiss-Prot database (dark gray). Bars
correspond to the percentage of proteins annotated with each GO term. Asterisks indicate significant enrichment relative to the number of identified
proteins (two-sided Fisher's exact test).
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rapamycin (mTOR) is modified on lysine 2066 following infection
with Listeria in wild-type animals, within the FKBP rapamycin-
binding domain54. mTOR is not only critical for the immune
response to pathogens but also negatively regulates the catabolic
process of autophagy, which can target bacteria for degradation in
the lysosome. A second autophagy regulator, the Ras-related pro-
tein RAB7A, also emerged from our analysis of ISG15 targets.
RAB7A is modified by ISG15 in the condition of deregulated
autophagy (USP18C61A/C61A KI mice). Notably, RAB7A is mod-
ified in close proximity to its GTP-binding domain at K126. In
other cases, ISGylation occurs near GTP-binding sites or active
sites of enzymes (Fig. 4b, d). Modification with a bulky di-
ubiquitin-like molecule at these sites could potentially hinder
enzymatic activity or GTPase function. While the proximity of
target lysines to these domains was not significantly closer than
that of other lysines on the same structure (Supplementary Fig. 3a),
our systematic gene ontology analysis revealed an enrichment in
nucleotide and ATP-binding proteins, as well as cofactor and
coenzyme-binding proteins (Fig. 2e, Molecular function panel). In
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Fig. 4 Structural analysis of ISGylated sites. a ISGylated site Lys2066 of serine/threonine-protein kinase mTOR (uniprot ID: Q9JLN9) is shown on the
structure PDB 5H64 [https://www.rcsb.org/structure/5H64]73. b ISGylated site Lys126 of Ras-related protein Rab-7a (uniprot ID: P51150) is shown on
the structure PDB 1VG8 [https://www.rcsb.org/structure/1VG8]74. c ISGylated site Lys440 of glucose-6-phosphate isomerase (uniprot ID: P06745) is
shown on the structure PDB 2CVP [https://www.rcsb.org/structure/2CVP]75. d ISGylated sites Lys23, Lys127, and Lys157 of phosphoglycerate kinase 1
(uniprot ID: Q9JII6) is shown on the structure PDB 4GAC [https://www.rcsb.org/structure/4GAC]76. a–d Relative solvent accessibility (RSA) is
computed using all available structures. The mean and the standard deviation are reported. Hydrogen bonds and electrostatic interactions are represented
by black dashed lines.
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isomerase and phosphoglycerate kinase 1 are also modified by
ISG15 following infection with Listeria either at dimerization
domains or at active sites of the enzyme (Fig. 4c, d). Taken toge-
ther, ISGylation of liver enzymes, modulators of growth factor
signaling, and catabolic pathways, suggests a new role for ISGyla-
tion in liver metabolism during infection.
ISGylation increases basal and infection-induced autophagy.
We were struck by the modification of four key regulators of
autophagy by ISGylation, in particular the modification of mTOR
and WIPI2 following infection in wild-type animals following
Listeria infection and modification of AMBRA1 and RAB7 fol-
lowing infection in USP18C61A/C61A animals. Given the particular
relevance of these proteins in the control of autophagy, we
explored whether this pathway is altered by ISG15 upon Listeria
infection. Autophagy is a catabolic, cellular response to starvation,
but it can also control targeting of intracellular pathogens to the
lysosome for degradation or indirectly alter a pathogen’s access to
cytosolic nutrients required for growth and replication. Listeria
expresses ActA to evade autophagy as it spreads from cell-to-
cell55. Recent work suggests that if ActA levels plunge, the bac-
terium can be trapped and replicate in a vacuole in hepatocytes in
a process that could potentially involve autophagic targeting56. We
reasoned that either of these pathways could be affected by altered
autophagy induction in USP18C61A/C61A animals or cells, where
ISG15 modification is enhanced. In order to address this question,
we generated mouse embryonic fibroblasts (MEFs) from wild-
type, USP18C61A/C61A, or Isg15−/− animals. We first assessed
ISGylation levels in wild-type versus USP18C61A/C61A cells fol-
lowing interferon treatment and found that levels of ISGylation in
USP18C61A/C61A MEFs relative to wild-type are much higher as
expected (Fig. 5a). Surprisingly, longer exposure using film
revealed that there is increased ISGylation prior to interferon
treatment as well (Supplementary Fig. 4a). We took advantage of
this unexpected increased ISGylation in fibroblasts to mimic
in vivo ISGylation following Listeria infection. Hyper-ISGylation
is as protective against Listeria infection as wild-type ISGylation in
tissue culture cells in contrast to Isg15-deficient fibroblasts, which
are highly susceptible to Listeria infection (Fig. 5b). In fact, upon
normalization of bacterial load across experiments, there is evi-
dence for a bimodal distribution, suggesting that in a subset of
cells hyper-ISGylation can be more protective than wild-type
ISGylation in a cell intrinsic manner similar to what was reported
for viral pathogens21. These findings support our previous work
that demonstrates that overexpression of ISG15 protects against
Listeria infection in non-phagocytic cells13. We next sought to
quantify autophagy in these cells by assessing endogenous con-
version of the autophagic marker LC3-I to LC3-II via SDS-PAGE
analysis (Fig. 5c). Autophagy was dramatically upregulated in
USP18C61A/C61A fibroblasts relative to wild-type cells prior to
infection at baseline, and autophagic flux was assessed by the
addition of Bafilomycin A which inhibits lysosomal acidification.
Infection with Listeria induced autophagy in both wild-type and
USP18C61A/C61A cells, however, this induction was dramatically
and significantly increased in cells with enhanced ISGylation
(Fig. 5c). Furthermore, the autophagy adaptor p62/SQSTM, which
is also targeted for degradation by autophagy, was reduced in
quantity in USP18C61A/C61A MEFs relative to wild-type MEFs at
baseline and was further degraded following Listeria infection; this
degradation could be partially but not completely halted by
Bafilomycin A treatment (Fig. 5c). Interestingly, ISG15 deletion
also increases autophagy, as was previously observed57, however,
p62 accumulates under these conditions, thus it seems that tar-
geting of autophagosomes to the lysosome may be impaired in
Isg15-deficient cells (Fig. 5c). We subsequently ectopically
expressed an autophagic marker, GFP-LC3, in wild-type,
USP18C61A/C61A and Isg15−/− fibroblasts and quantified basal
autophagy, as well as autophagy following infection by enumer-
ating LC3 puncta (Fig. 5d, e). Across all conditions, there were
significantly more LC3 puncta per cell in USP18C61A/C61A fibro-
blasts than in wild-type cells, whereas Isg15−/− cells displayed an
intermediate phenotype that was not significantly different from
either wild-type or USP18C61A/C61A cells, and did not increase in
Bafilomycin A treated cells supporting an impairment in traf-
ficking. Finally, we wondered whether the effect on autophagy
induction would also occur in vivo following Listeria infection. We
assessed LC3-II levels in liver homogenate isolated from wild-type
and USP18C61A/C61A animals following 72 h of infection and
found increased LC3-I as well as LC3-II in USP18C61A/C61A ani-
mals (Fig. 5f). Taken together, as predicted by our global ISGy-
lome analysis, modification of key modulators of autophagy led to
increased basal and infection-induced activation of this pathway
in both cells and animals with enhanced ISGylation.
In order to determine whether ISG15 modification of autophagy
regulators has a direct effect on LC3 turnover, we chose to focus on
mTOR since it plays such a critical role in growth and metabolism.
ISG15 targets K2066 of mTOR which lies in the FKPB/Rapamycin-
binding domain (FRB) (Fig. 6a, b). In order to validate
modification of mTOR by ISG15, we transfected HEK293T cells
with ISG15, its E1, E2, E3, and mTOR58 (Fig. 6c). ISGylated mTOR
was visible following transfection and immunoprecipitation of
wild-type ISG15, but not with a mutant of ISG15 that is unable to
conjugate (ISG15AA). In addition, we validated modification of
Myosin 959, HSP9060, and glucose-6-phosphate isomerase 1
(mGPI-1) (Supplementary Fig. 5a–c). Since overexpression in this
system is reported to lead to promiscuous cotranslational
modification of accessible lysines29, we endeavored to validate
endogenous modification of mTOR in USP18C61A/C61A MEFs that
were treated with IFN as a model for in vivo infection. Upon
immunoprecipitation of endogenous mTOR, a clear doublet
corresponding to ISG15 is present in the USP18C61A/C61A, but
not in Isg15−/− or wild-type MEFs (Fig. 6d). Probing immuno-
precipitated mTOR with antibodies against ubiquitin or NEDD8
did not reveal modification by these proteins, which further
validates the identification of bone fide ISG15 sites by our
approach (Supplementary Fig. 5e–g). The doublet could represent
two individual mono-ISGylation sites or a chain of ISG15
molecules given our observation of sites on ISG15 itself. Since we
only quantified one modification site on mTOR, we mutated this
lysine, K2066, to arginine and assessed the effect of this mutation
on autophagy induction in a human hepatocellular carcinoma cells
Huh-7 (Fig. 6e). Amino acid starvation of these cells led to an
increase in LC3-II as expected, ectopic expression of mTOR
K2066R induced relatively less LC3-II than wild-type mTOR or
mock transfected cells, indicating that ISGylation of mTOR could
repress its activity. This observation, however, was made in cells
that harbor endogenous mTOR, therefore future work to assess the
effect of a gene-edited KR mutant in the absence of wild-type
mTOR as well as in other ISG15 substrates from our analysis will
be of interest to mechanistically assess the effect of ISGylation on
specific target lysines. Taken together, mTOR is ISGylated on
lysine K2066 in the liver of Listeria-infected animals, we validated
that this modification occurs in vitro in both human and mouse
cells and mutating lysine 2066 to arginine has a repressive effect on
the downstream process of autophagy in an overexpression model
in human liver cells.
Discussion
Here, we have devised a strategy combining murine models of
ISG15 deficiency and enhanced ISGylation with quantitative
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label-free proteomics to map the endogenous liver ISGylome in
animals infected with the bacterial pathogen, Listeria mono-
cytogenes. We have identified and distinguished bona fide ISGy-
lated sites from ubiquitin sites in vivo. We have mapped 930
ISG15 sites on 434 proteins, which is a substantial increase from
previous studies of ISG15 conjugation. In addition, we have
observed that ISG15 modification occurs at known acetylation
sites following infection, and on extracellular/secreted and
mitochondrial proteins. We have observed that ISG15 modifica-
tion targets metabolic pathways and through a computational
analysis of available structures of ISG15 target proteins have
highlighted that ISG15 often modifies sites of protein dimeriza-
tion or catalytic sites of enzymes. We validated our findings by
assessing the role of modification of known regulators of the
catabolic process of autophagy and found that basal and
infection-induced autophagy were increased in cells and animals
with enhanced ISGylation (USP18C61A/C61A).
The enrichment of adducts of specific posttranslational mod-
ifications left following trypsin digestion has revolutionized the
understanding of the ubiquitin code, the acetylome, and helped to
systematically identify the SUMOylome as well61. ISG15 has been
challenging to study due to its absence in genetically tractable
model organisms such as yeast, its multiple modes of action (as a
cytokine, covalent modification and non-covalent interaction), its
absence prior to induction following infection and its C-terminal
LRLRGG motif, which is indistinguishable from that of ubiquitin
or NEDD8. Initial identification of ISG15 substrates following
ectopic expression, enrichment, and affinity purification sug-
gested widespread and relatively promiscuous modification of the
proteome in either human cells or mouse cells deficient in
USP1841,43,62. However, these studies relied on ectopic expression
of ISG15, its E1, E2, and E3 as well as its substrate or treatment
with interferon in tissue culture cells, conditions which may not
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Fig. 5 ISGylation alters basal and infection-induced autophagy. a SDS-PAGE of wild-type, USP18C61A/C61A, and Isg15−/− mouse embryonic fibroblasts
treated with interferon β (1000 units/mL for 24 h), bottom ISG15 blot is a short exposure of the upper panel. b Mouse embryonic fibroblasts MEFs (wild-
type, Isg15−/− KO, and USP18C61A/C61A KI) were infected with Listeria monocytogenes strain EGD for 4 h at an MOI of 10. Cells were lysed, and bacterial
CFUs were enumerated through serial dilution. Wild-type values were normalized to 100; data from three independent experiments are shown. Statistical
analysis was conducted using one-way ANOVA and Tukey’s test post hoc. c SDS-PAGE analysis of wild-type or USP18C61A/C61A MEFs treated with
Bafilomycin A (100 nM for 20min prior to lysis) at baseline or following 4 h of infection with Listeria at an MOI of 10. Immunoblot is a representative image
of five independent experiments. d GFP-LC3 puncta per cell; data shown are compiled from four separate experiments WT (un, un+ Baf, EGD, EGD+ Baf)
n= 408, 450, 984, 987 (USP18C61A/C61A (un, un+ Baf, EGD, EGD+ Baf) n= 352, 410, 1038, 1014, Isg15−/− (un, un+ Baf, EGD, EGD+ Baf) n= 183, 224,
710, and 470 individual cells per condition were enumerated). Statistical analysis was conducted using one-way ANOVA and Tukey’s test post hoc (exact
p-values (Supplementary Fig. 4b). NS nonsignificant, *p < 0.05; **p < 0.01; ***p < 0.001 ****p < 0.0001. e Representative images of cells stably expressing
GFP-LC3 and treated as above with Bafilomycin A or infected with Listeria and treated with Bafilomycin A, scale bar is 5 μm. f SDS-PAGE of liver
homogenate from n= 4 individual animals either wild-type or USP18C61A/C61A infected with 5 × 105 Listeria, organs harvested following 72 h of infection.
Raw data are available in the source data file.
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13393-x ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5383 | https://doi.org/10.1038/s41467-019-13393-x | www.nature.com/naturecommunications 9
mTOR
ISG15
IFN + + ++ + +




































+ –HA-ISG15 AA + –
HA-ISG15 WT +– +–





























Huh-7 hepatocellular carcinoma cells
Fig. 6 mTOR is modified by ISG15 and mutation of K2066 to arginine results in reduced autophagy. a Schematic of the domains of mTOR with the target
lysine highlighted. b ISGylated site Lys2066 of serine/threonine-protein kinase mTOR (uniprot ID: Q9JLN9) is shown in orange on the structure PDB 5H64
[https://www.rcsb.org/structure/5H64]73. c Validation of modification of mTOR by ISG15 in HEK293T overexpression system (simultaneous
overexpression of E1, E2, E3, mTOR, and ISG15, either wild-type or non-conjugatable ISG15AA); asterisk indicates FLAG-HERC5; SDS-PAGE of input and
immunoprecipitation of ISG15. d Validation of endogenous modification of mTOR by ISG15 in mouse embryonic fibroblasts treated with Type I IFN (1000
units/mL) for 24 h. Immunoprecipitation of endogenous mTOR and SDS-PAGE for both mTOR and ISG15. Modified ISG15 is only detectable in USP18C61A/
C61A MEFs. The experiment was repeated three times, and one representative blot is shown. e Ectopic expression of either wild-type mTOR (WT) or mTOR
K2066R (KR) in Huh-7 liver cells untreated or HBSS starved (4H) and/or treated with Bafilomycin A (100 nM for 30min prior to lysis). The experiment
was repeated three times, and one representative blot is shown. Raw data are available in the source data file.
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of the whole organism. Since then, there have not been any large-
scale, quantitative ISGylomes published. Here, we contribute a
large-scale map of endogenous ISG15 sites in a relevant infection
setting in vivo. Furthermore, our strategy allowed us to determine
the strict ubiquitylome in liver tissue from Isg15−/− animals prior
to and following infection with Listeria monocytogenes in order to
identify the ISGylome. In and of itself, the in vivo ubiquitylome
following Listeria infection had not yet been mapped and similar
to what is observed in cells Listeria provokes a downregulation of
many ubiquitylated targets46. In addition, our data confirmed the
existence of mixed ISG15-ubiquitin chains in vivo on K29 of
ubiquitin as previously reported and potentially on K6, which had
not yet been observed53. Our analysis also revealed sites of pos-
sible ISG15 chains, the function of which remains to be explored.
Our method led to the identification of 614 ISG15 sites on 292
proteins following infection in wild-type animals and 316
ISG15 sites on 219 proteins in USP18C61A/C61A animals, out of
~5000 total identified sites (18.6% of sites following Listeria
infection). This percentage indicates that ISG15 is a less abundant
modification than SUMO or ubiquitin, which is in line with our
previous findings13. However, this number of sites also implies
that some previously identified ubiquitin sites may in fact be
misidentified ISG15 sites. Following in vitro viral infection,
interferon treatment or overexpression of ISG15, along with its
E1, E2, E3, and a target, cotranslational modification has been
reported29. Our data suggest that during Listeria infection in vivo,
modification of infection-induced proteins constitutes around
12% of modified proteins during wild-type infection (from cluster
2) and 18% during enhanced ISGylation (cluster 1) by contrast
with 25% of ubiquitin substrates (proteins modified that are also
upregulated by infection, cluster 3). It will be informative to assess
whether viral infection causes a higher rate of infection-induced
protein modification than bacterial infection or whether this
phenomenon varies from one tissue or cell type to another. Our
approach took advantage of Isg15-deficient animals, however, one
potential caveat could be that the lack of ISG15 provokes com-
pensatory changes in ubiquitin sites or levels. We attempted to
assess this possibility with SDS-PAGE and quantitative pro-
teomics of diglycine sites prior to infection and did not find
substantive differences between Isg15−/− and wild-type. How-
ever, using newly available methods such as UbiSite to assess
ubiquitin levels in Isg15−/− animals or cells would definitively
address this caveat45. Recently, an elegant biochemical study
characterizing a viral effector called LB(Pro) from foot-and-
mouth-disease-virus revealed its function as an ISG15 iso-
peptidase which can also be exploited to identify ISG15 sites63.
One potential challenge of using a viral protein to identify sites
lies in controlling and demonstrating its specificity for ISG15 or
ubiquitin, thus future studies comparing substrates from each
method would be timely and relevant to identify a core list of
ISG15 sites as well as sites that could potentially be unique to
specific biological conditions or infections.
This data set reveals many unexpected findings while also con-
firming previously described observations. If any cellular compart-
ment is particularly enriched across all ISG15 clusters, it is
extracellular or secreted proteins, which supports the role of ISG15
in exosome secretion, though TSG101 was not specifically identified
as a substrate following Listeria infection32. USP18 is concomitantly
upregulated with ISG15 following Listeria infection and whether
this is to temporally regulate specific targets or to alter STAT sig-
naling remains to be determined. Therefore, the USP18C61A/C61A
ISGylome could potentially represent a distinct subset of
ISG15 substrates, which could hypothetically need to be more
rapidly removed during the course of an infection for proper
antibacterial immunity. Thus, cluster 2 (proteins present in wild-
type, but absent in Isg15−/− following infection) is likely the closest
approximation of the wild-type ISGylome following Listeria infec-
tion. Cluster 2 displays increased overlap with known acetylation
sites, as well as modification of mitochondrial proteins. Protein
acetylation in the nucleus, cytosol, and mitochondria controls a
variety of cellular functions from gene expression to metabolic
pathways and can be modulated by the NAD+ -dependent protein
deacetylases Sirtuin1-7. Previous work has highlighted the impor-
tance of histone deacetylation by Sirtuin 2 for transcriptional
reprogramming of an infected cell64. Our current work implies that
other Sirtuins could also be important for metabolic reprogram-
ming in concert or in competition with ISGylation. One enigmatic
finding from the ISG15 literature is the presence of ISGylated
conjugates within the mitochondria as determined by protection of
ISG15 chains from proteinase K digestion52. At least some of the
sites on mitochondrial proteins that we identified are located within
the inner mitochondrial membrane, and how this occurs topolo-
gically remains to be elucidated.
The gene ontology analysis also unearthed enrichment in
cofactor and nucleotide-binding proteins and a variety of metabolic
pathways. Since we did not find a particular ISG15 motif in either
cluster, we analyzed the topography of solved protein structures
surrounding the modified lysine. In several cases, sites of dimer-
ization were targeted by ISG15, as were active sites of enzymes. The
liver is a site of immune surveillance, metabolic activity, and
detoxification of blood, therefore ISGylation may be a unique
modification that transmits an alarm signaled by bacterial or viral
infection and has metabolic consequences. If modification at sites
of dimerization or active sites of metabolic enzymes does reduce
the activity of these enzymes, it could be another tool in the arsenal
against pathogens that otherwise could usurp cellular metabolites
for their own survival and replication. We were intrigued by the
modification of the autophagy modulators mTOR, WIPI2,
AMBRA1, and RAB7 because modification of mTOR in the FKBP/
Rapamycin-binding domain could act to repress its function in
growth and metabolism while upregulating the process of xeno-
phagy. The effect of the K2066R mTOR mutant on autophagy
induction would support this hypothesis, however, as previously
mentioned, this effect was observed in the presence of wild-type
mTOR. Future work in a deletion or knockdown background will
be even more informative. The consequences of modification sites
on WIPI2 and AMBRA1 are more difficult to predict given less is
known with regard to their structural features, so we assessed
general autophagy levels following infection. Indeed, basal and
infection-induced autophagy were increased in USP18C61A/C61A
cells and animals relative to wild-type. Previous work has reported
modification of the autophagy regulator Beclin-1 by ISGylation57,
however, this specific modification does not appear to occur during
Listeria infection. Within cells elevated autophagy led to wild-type
or slightly better clearance of bacteria as would be predicted,
however, the cell extrinsic role of USP18C61A/C61A mutation
in vivo led to a higher bacterial load potentially through the pre-
viously reported pleiotropic effects on signaling or cytokine
secretion, which could favor Listeria replication following
unchecked ISGylation. Future work will tackle these discrepancies
by assessing the relative contribution of cytokine secretion versus
autophagy induction on bacterial burden in vivo. Taken together,
we have generated a comprehensive map of ISG15 sites to pave the
way to understanding the consequences of ISG15 modification on
protein fate and function. In addition, the strategy established here
provides a previously unavailable tool to globally identify endo-
genous and pathogen-derived ISGylation substrates within the
context of the whole organism.
Methods
Materials. We used an α-ISG15 antibody from Santa Cruz (F-9) at 1:200, an α-
SQSTM1/p62 antibody from Abcam, UK (ab56416) at 1:1000. We used an α-LC3
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antibody from MBL, Japan (M152-3, clone 4E12) at 1:1000 and an α-ACTIN
antibody from Sigma, Saint Louis, MO (AC-15, A5441) at 1:5000. We used an α-
mTOR antibody from Sigma (PA5-34663) at 2 µg/sample for immunoprecipita-
tion, an α-mTOR antibody from Cell Signaling (7C10) at 1:1000, an α-tubulin
antibody from Sigma (T6074) at 1:5000, an α-ubiquitin antibody from Cell Sig-
naling (P4D1) at 1:1000, and an α-NEDD8 antibody from Cell Signaling (19E3) at
1:1000. We used an α-HA antibody from Sigma (H6908) at 1:1000 for immuno-
blotting, and an α-GFP antibody from Santa Cruz Biotechnology (sc-81045) at
1:1000. We used an α-FLAG® M2 antibody from Sigma (F3165) at 1:10,000, an α-
HA tag antibody—ChIP Grade from Abcam, UK (ab9110) at 1:5000, and an α-
alpha-tubulin antibody from Genetex (GT114) at 1:40,000. We used α-HA anti-
body magnetic beads from Pierce (88837), and anti-flag antibody magnetic beads
from Sigma (M2 M8823 Millipore) for immunoprecipitation.
Bacterial and mammalian growth conditions and infections. Listeria mono-
cytogenes strain EGD (BUG 600) was used for all infections in this study. Listeria
was grown in Brain Heart Infusion media (BD). Prior to infection, overnight
cultures of bacterial strains were diluted in new media and grown to exponential
phase (OD 0.8–1), washed three times in serum-free mammalian cell culture
media, and resuspended in mammalian cell culture media at the indicated MOI. A
fixed volume was then added to each well. Cells were centrifuged for 1 min at
201 × g to synchronize infection. The cells were then incubated with the bacteria for
1 h at 37 °C, 5% CO2. Following this incubation, the cells were washed at room
temperature with 1× PBS, and cell growth medium with 10% serum was added
with 20 μg/ml gentamicin to kill extracellular bacteria. The cells were then har-
vested at the indicated time point to collect bacteria for colony-forming units or to
collect protein lysates for SDS-PAGE analysis. Mouse embryonic fibroblasts were
grown in DMEM with Glutamax (Gibco, Waltham, MA) supplemented with 10%
fetal bovine serum. Primary mouse embryonic fibroblasts were transformed
through transfection (Fugene HD, Promega) with a plasmid containing the SV40
Large T antigen. Retrovirus was generated by transfection of Phoenix cells (ATCC
CRL-3213) with pBabe puro GFP-LC3 (Plasmids listed in Supplementary Data 6)
using Fugene HD. In all, 1.5 ml of collected virus was mixed with 500 μl of con-
ditioned media of MEFs supplemented with 8 μg/ml polybrene (Millipore), and
applied to MEFs. Virus was collected and applied to MEFs in the presence of
polybrene (Millipore) as described (in the protocol “Production of retroviruses
using Fugene 6” from the Weinberg lab on Addgene). Cells were then selected
using 2 μg/ml puromycin for 3 days. The population of cells that survived pur-
omycin treatment was expanded and tested for GFP-LC3 expression. For main-
tenance, cells were initially grown without puromycin, however, we observed that
the USP18C61A/C61A cells with GFP-LC3 would lose expression over time, likely
due to deleterious levels of autophagy, therefore we were required to maintain the
cells in puromycin.
Overexpression systems in tissue culture. Huh-7 cells (obtained from the
laboratory of Eliane Meurs at Institut Pasteur) were transfected (Fugene HD, Pro-
mega) with 0.5 µg of myc-mTOR or myc-mTOR K2066R. Forty-eight hours post
transfection, cells were starved without amino acids with HBSS Ca2++Mg2++
medium for 4 h. Cells were treated with bafilomycin A1 (100 nM) for 30 min and
subsequently lysed with 1× RIPA lysis buffer supplemented with Complete Mini
Protease inhibitor cocktail (Roche). HEK293T (obtained from Prof. Sven Eycker-
man) or HeLa (obtained from ATCC—CCL2™) cells were grown to ~80% con-
fluence in DMEM+ 10% FBS and 1% P/S before being transfected with E1/E2/E3,
and HA-ISG15-LRGG or HA-ISG15-LRAA using polyethylenimine (PEI). After
24 h, they were transfected with mGpi1-FLAG, GFP-MYH9, or eGFP-HSP90-β for
another 24 h or 48 h. Plasmids used: pcDNA3.1-HA-ISG15, pcDNA3.1-HA-ISG15-
LRAA, pcDNA3.1-hUbe1L (E1), pcDNA3.1-UbcM8 (E2), pcDNA3.1-Ubch8 (E2),
pTriEx2-hHERC5 (E3), pCMV6-mGpi1-FLAG (Origene), pCMV-GFP-MYH9,
pEGFP-HSP90-β (Supplementary Data 6). Cell lines are tested for mycoplasma
prior to expansion in the laboratory, and subsequently 2–3 times per year or if they
exhibit symptoms (slow growth, increased cell death following transfection or
infection). We did not use ICLAC cell lines in this study, but two cell lines
(HEK293T and HeLa) were authenticated by PCR single-locus technology by
Eurofins on March 20, 2019.
SDS-PAGE. For the SDS-PAGE analysis of fibroblasts, cells were trypsinized
(0.05% trypsin, Invitrogen) and lysed in 1% Triton lysis buffer supplemented with
Complete Mini Protease inhibitor cocktail (Roche). Gels were transferred using an
iBLOT transfer system (Invitrogen), blocked in 5% milk for 1 hr at RT, incubated
with primary antibody overnight at 4 °C, washed with 0.05% Tween in PBS three
times (each wash for 7 min), and incubated for 1 h at room temperature with
secondary antibody coupled to HRP. Blots were washed again three times with
0.05% Tween in PBS and revealed using ECL Western Blotting Substrate (Pierce,
Waltham, MA).
Immunoprecipitation. Cells were lysed and protein concentration was determined
with either a Bradford or BCA assay. In total, 2 mg of total protein were used for
either FLAG-, GFP-, or HA-immunoprecipitation, using FLAG-M2 Affinity gel
(Merck), µMACS HA isolation kit (Milteny Biotec) or Anti-HA magnetic beads
(Pierce) and GFP-Trap® (ChromoTek) according to the manufacturer’s instruc-
tions. We expanded mouse embryonic fibroblasts to 12 75-cm2 dishes per geno-
type. Six dishes of each genotype were treated with recombinant mouse type I
interferon IFN-alpha A protein (R&D system) at 1000 U/ml for 24 h, and the other
six dishes were untreated. At 24 h, posttreatment cells were lysed in 6 ml of RIPA
lysis buffer per 75-cm2 dish. The lysates from six dishes were combined for each
condition, treated with universal nuclease for 2 h at 4 °C (Pierce) and centrifuged.
The pellet was discarded, and the protein concentration in the lysate was measured
using a BCA assay (Pierce). In all, 1 mg of protein from each condition was used for
subsequent immunoprecipitation. Each sample was incubated with 2 µg of mTOR
antibody at 4 °C for 72 h. Antibody-mixed samples were then incubated with 40 µl
slurry of protein A/G magnetic agarose beads (Thermo Scientific) at 4 °C for 3 h.
Beads were pulled down with a magnet (Dyna Mag2, Invitrogen) and washed three
times with cold 1× PBS. Proteins were eluted from beads with 0.1 M glycine,
pH 2.5, and immediately neutralized with alkaline neutralization buffer, pH 8.0.
Eluates were reduced with 1x sample buffer supplemented with 10% β-
mecaptoethanol and heated at 95 °C for 5 min.
Microscopy and image processing. Cells were plated on coverslips the day prior
to an experiment. Cells were fixed in 4% PFA (Electron Microscopy Sciences,
Hatfield, Pennsylvania) in PBS for 15 min at room temperature. Coverslips were
mounted using ProLong Diamond antifade mounting media (Thermo Fisher Sci-
entific, USA), and images were acquired using an inverted wide-field fluorescence
microscope (Axio Observer 7, Carl Zeiss Microscopy, Germany) equipped with an
Axiocam 506 mono camera and the software ZEN 2.3 Pro. Images were processed
using ImageJ65,66 in 16-bit and were auto-contrasted with Renyi Entropy threshold
preset for optimal resolution. Puncta were counted using the particle analyze
function (size threshold: 1–12 pixels). LC3 puncta were enumerated and divided
per nuclei within each field. At least 100 cells were counted per experiment, and the
data were compiled from three independent experiments. Statistical analysis was
conducted using one-way ANOVA and Tukey’s test post hoc.
In vivo infections. Female C57BL/6 mice (Usp18+/+ or USP18C61A/C61A) were
infected intravenously between 8 and 12 weeks of age with 5 × 105 bacteria per
animal and sacrificed 72 h following infection. Colony-forming units per organ (liver
or spleen) were enumerated after tissue dissociation and serial dilutions in sterile
saline. For the SDS-PAGE of animal samples, wild-type mice were infected intra-
venously with Listeria or injected with sterile saline solution, and sacrificed after 72 h.
The liver and spleen were isolated and dissociated. Tissue homogenates were then
centrifuged at 19,283 × g for 10min at 4 °C. For liver tissue, an aliquot of the soluble
fraction below the layer of fat was removed and resuspended in 2x Laemmli buffer.
The samples were then run on an SDS-PAGE gel and blotted for ISG15 and actin
levels.
Statistical methods. To determine statistical significance in animal experiments,
nonparametric analyses were used since the n is too low to determine normal
distribution. We used a two-tailed Mann–Whitney test, exact p-values are dis-
played. For enumeration of GFP-LC3 punta and in vitro infection assays, we used
one-way ANOVA followed by Tukey’s test post hoc. The statistical methods for the
proteomics analysis are discussed in the proteomics methods.
Ethics statement. This study was carried out in strict accordance with the French
national and European laws and conformed to the Council Directive on the
approximation of laws, regulations, and administrative provisions of the Member
States regarding the protection of animals used for experimental and other sci-
entific purposes (86/609/Eec). Experiments that relied on laboratory animals were
performed in strict accordance with the Institut Pasteur’s regulations for animal
care and use protocol, which was approved by the Animal Experiment Committee
of the Institut Pasteur (approval number no. 03–49).
Proteomics sample preparation. Three C57BL6/J mice per genotype and per
condition (Isg15+/+, Isg15−/−, and USP18C61A/C61A) were injected intravenously
with 5 × 105 Listeria monocytogenes strain EGD or PBS (carrier control), and were
monitored and weighed daily. Seventy-two hours post infection, animals were
sacrificed, and whole livers were collected and flash-frozen in liquid nitrogen. The
livers were homogenized in 10 ml urea lysis buffer containing 9M urea, 20 mM
HEPES pH 8.0, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate,
1 mM β-glycerophosphate. Samples were sonicated by three pulses of 10 s at an
amplitude of 20% and centrifuged for 15 min at 16,000 × g at room temperature to
remove insoluble components. The protein concentration in the supernatants of
each replicate was measured using a Bradford assay (Biorad) and equal protein
amounts, each containing 10 mg total protein, were used for further analysis.
Proteins in each sample were reduced by adding 5 mM DTT and incubation for
30 min at 55 °C. Alkylation of the proteins was done by addition of 10 mM
chloroacetamide for 15 min at room temperature in the dark. The samples were
diluted with 20 mM HEPES pH 8.0 to a urea concentration of 2M, and the pro-
teins were digested with 100 µg trypsin (Promega) (1/200, w/w) overnight at 37 °C.
Immunocapture of GG-modified peptides was then performed using the
PTMScan® Ubiquitin Remnant Motif (K-ε-GG) Kit (Cell Signaling Technology)
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according to the manufacturer’s instructions. Briefly, peptides were purified on
Sep-Pak C18 cartridges (Waters), lyophilized for 2 days, and re-dissolved in 1.4 ml
1x immunoprecipitation buffer supplied with the kit. Note that at this point, ali-
quots corresponding to 100 µg of digested protein material were taken for shotgun
proteomics analysis. Peptides were incubated with the antibody-bead slurry for 2 h
on a rotator at 4 °C and after several wash steps, GG-modified peptides were eluted
in 100 µl 0.15% TFA and desalted on reversed phase C18 OMIX tips (Agilent), all
according to the manufacturer’s protocol. Purified GG-modified peptides were
dried under vacuum in HPLC inserts, and stored at −20 °C until LC-MS/MS
analysis.
LC-MS/MS and data analysis. Purified GG-modified peptides were re-dissolved
in 20 µl loading solvent A (0.1% TFA in water/ACN (98:2, v/v)) of which 8 µl was
injected for LC-MS/MS analysis on an Ultimate 3000 RSLCnano system in-line
connected to a Q Exactive HF mass spectrometer (Thermo). Trapping was per-
formed at 10 μl/min for 4 min in loading solvent A on a 20 mm trapping column
(made in-house, 100-μm internal diameter (I.D.), 5-μm beads, C18 Reprosil-HD,
Dr. Maisch, Germany) and the sample was loaded on a 400 -mm analytical column
(made in-house, 75 µm I.D., 1.9 -µm beads C18 Reprosil-HD, Dr. Maisch). Peptides
were eluted by a nonlinear increase from 2 to 56% MS solvent B (0.1% FA in water/
acetonitrile (2:8, v/v)) over 140 min at a constant flow rate of 250 nl/min, followed
by a 15-min wash reaching 99% MS solvent B and re-equilibration with MS solvent
A (0.1% FA in water/acetonitrile (98:2, v/v)). The column temperature was kept
constant at 50 °C in a column oven (CoControl 3.3.05, Sonation). The mass
spectrometer was operated in data-dependent mode, automatically switching
between MS and MS/MS acquisition for the 16 most abundant ion peaks per MS
spectrum. Full-scan MS spectra (375–1500 m/z) were acquired at a resolution of
60,000 in the orbitrap analyzer after accumulation to a target value of 3,000,000.
The 16 most intense ions above a threshold value of 13,000 were isolated for
fragmentation at a normalized collision energy of 32% after filling the trap at a
target value of 100,000 for maximum 80ms. MS/MS spectra (200–2000 m/z) were
acquired at a resolution of 15,000 in the orbitrap analyzer. From the aliquots for
shotgun proteomics analysis, ~3 µg of peptides were injected on the same LC-MS/
MS system, using similar settings as described above. Here, the 16 most intense
ions above a threshold value of 22,000 were isolated for fragmentation after filling
the trap at a target value of 100,000 for maximum 45ms.
Data analysis was performed with MaxQuant (version 1.5.4.1) using the
Andromeda search engine with default search settings including a false discovery
rate set at 1% on both the peptide and protein level. Two different searches were
performed to analyze the spectra from the GG-enriched samples and the shotgun
samples. In both searches, spectra were interrogated against mouse proteins in the
Uniprot/Swiss-Prot database (database release version of May 2016 containing
16,789 mouse protein sequences, [www.uniprot.org]) as well as proteins from L.
monocytogenes strain EGD (Taxonomy ID 1334565, containing 2806 Listeria
sequences, [http://www.ncbi.nlm.nih.gov/]) with a mass tolerance for precursor
ions of 4.5 ppm, and a mass tolerance for fragment ions of 20 ppm and 0.5 Da for
the GG-enriched and the shotgun samples, respectively. Enzyme specificity was set
as C-terminal to arginine and lysine (trypsin), also allowing cleavage at arginine/
lysine–proline bonds with a maximum of three missed cleavages for the GG-
enriched samples and a maximum of two missed cleavages for the shotgun
samples. Carbamidomethylation of cysteine residues was set as a fixed modification
in both searches, and variable modifications were set to oxidation of methionine (to
sulfoxides) and acetylation of protein N-termini. The minimum score for modified
peptides was set to 30 and for the GG-enriched samples, GlyGly modification of
lysine residues was set as an additional variable modification. In both searches,
matching between runs was enabled with an alignment time window of 20 min and
a matching time window of 1 min. From the shotgun analysis, only proteins with at
least one unique or razor peptide were retained leading to the identification of 4146
mouse proteins (listed in the proteinGroups table), while from the GG-enriched
samples 5461 potential ISG15 or ubiquitin sites (listed in the GlyGly (K) Sites table)
were identified.
Further data analysis was performed with the Perseus software (version 1.5.5.3)
after loading the GlyGly (K)Sites table from MaxQuant. Reverse database hits were
removed, as well as potential contaminants. The site table was expanded, intensities
were log2 transformed and normalized for each sample by subtracting the median
intensity. Replicate samples were grouped, sites with less than three valid values in
at least one group were removed, and missing values were imputed from a normal
distribution around the detection limit. To reveal sites that were significantly
regulated, sample groups were defined based on infection (uninfected vs. EGD) and
genotype (WT vs. Isg15−/− vs. USP18C61A/C61A) and a two-way ANOVA test was
performed to compare the intensities of the sites in the infection group with the
genotype group. For each modification site, this test calculated a p-value (actually
−log p-value) for infection and a p-value for genotype. In total, 2166 sites with a
p-value < 0.01 in at least one of both groups were considered to be significantly
regulated. The intensities of these sites are further shown in a heatmap in Fig. 2a
after non-supervised hierarchical clustering. The significantly regulated
modification sites are reported in the Supplementary Data 1. To reveal ubiquitin
sites that were regulated during infection, a t test (FDR= 0.05 and S0= 1) was
performed only comparing GlyGly(K) sites in samples from Isg15−/− mice.
Quantified GlyGly(K) sites (n= 3055) and the results of the t tests are shown in
Fig. 3a, and are listed in Supplementary Data 5. For the analysis of the shotgun
data, the proteinGroups table from MaxQuant was loaded in Perseus, reverse
database hits were removed as well as proteins only identified by sites. The LFQ
intensities were log2 transformed and normalized for each sample by subtracting
the median LFQ intensity. Replicate samples were grouped, proteins with less than
three valid values in at least one group were removed and missing values were
imputed from a normal distribution around the detection limit. To reveal the
proteins that were significantly regulated, samples were grouped similarly as
described above, and a two-way ANOVA test was performed to compare the LFQ
intensities of the proteins in the infection group with the genotype group. In total,
1725 proteins with a p-value < 0.01 in at least one of both groups were considered
to be significantly regulated. The LFQ intensities of these proteins are further
shown in a heatmap in Supplementary Fig. 2c after non-supervised hierarchical
clustering. The significantly regulated proteins are reported in the Supplementary
Data 3. Since only two major clusters were observed in the heatmap, a t test was
performed (FDR= 0.05 and S0= 1) to compare protein intensities between all
infected and all noninfected samples. Quantified proteins (n= 3055) and the
results of the t test are listed in Supplementary Data 4 and shown in the volcano
plot in Fig. 3a. The significantly up- and downregulated proteins from this test were
used to calculate the percentage of sites overlapping with known ubiquitination or
acetylation sites in Fig. 2c. GO terms enrichment analyses were performed using
the Gene Ontology consortium bioinformatics resources67,68. All mass
spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the data set identifier
PXD011513. The project name is “Proteomics-based identification of ISG15
modification sites during Listeria monocytogenes infection.”
Sequence conservation analysis. Ortholog sequences for each protein was
retrieved from MetaPhOrs69 by the application programming interface (API)
access using “dbClient” module in python [https://github.com/lpryszcz/
metaphors_api]. One set of ortholog sequences was compiled for each given
UniProt protein ID. Multiple sequence alignment was performed using MAFFT
version 7.157b70 for each set of ortholog sequences. Sequence conservation was
computed by the occurrence frequency of Lys at the site of interest among the
given set of ortholog sequences. Names of species with ISGylation was retrieved
from NCBI [https://www.ncbi.nlm.nih.gov/gene/?term=ISG15].
Structural analysis of available structures. Structure for each protein was
retrieved from Protein Data Bank (PDB) using the “uniprot” module [https://pypi.
org/project/uniprot/] in python. If there were multiple structures available for a
given protein, all structures would be retrieved and analyzed. The solvent acces-
sibility of each site of interest was computed using DSSP [http://www.cmbi.ru.nl/
dssp.html]71. The relative solvent accessibility (RSA) was then computed by nor-
malizing the solvent accessibility to the maximum allowed solvent accessibility
reported in ref. 72. All protein structures were rendered and visualized in PyMOL
[https://pymol.org].
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
We have deposited the proteomic data on the PRIDE database with the data set identifier
PXD011513 [http://proteomecentral.proteomexchange.org/cgi/GetDataset?
ID=PXD011513]. The project name is “Proteomics-based identification of ISG15
modification sites during Listeria monocytogenes infection” and the code has been
uploaded to Github (Listeria ISGylome, https://github.com/wchnicholas/
Listeria_ISGylome). The source data underlying Figs. 1b–d, 5a–d, f, 6c–e, and
Supplementary Figs. 1a–e, 4a, and 5a–g are provided as a Source Data file. Compiled
experiments are also shown with individual units as circles on each graph, thus primary
data is displayed on each figure as well. All other data are available from the
corresponding authors upon reasonable request.
Code availability
Custom python scripts for analyzing the deep mutational scanning data have been
deposited to GitHub: Listeria ISGylome, https://github.com/wchnicholas/
Listeria_ISGylome.
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